Eledon Pharmaceuticals, Inc.

Thank you for your patience. Please remain connected. Your call will begin shortly. And all, once again, we thank you for your patience. Please remain on the line. Your call will begin in approximately one minute. Thank you. Greetings all, and welcome to the Elladon Pharmaceuticals Report's first quarter 2021 financial results. During the presentation, all participants will be in a listen-only mode. Afterwards, we will conduct a question and answer session. At that time, if you have a question, please press the one followed by the four on your telephone. Should you require operator assistance at any time, please press star zero. As a reminder, this call is being recorded today, Thursday, May 13th, 2021. I'd now like to turn the call over to John Kuwahara, Senior VP of Finance. Please go ahead.

Good afternoon, and thank you all for joining Elladon Pharmaceuticals' first quarter 2021 financial results conference call. Joining me today are three members of our leadership team, David Alexander-Grove, Chief Executive Officer, Steve Perrin, President and Chief Scientific Officer, and Paul Little, Chief Financial Officer. Earlier today, Eladon issued a press release announcing financial results for the first quarter ended March 31, 2021. You may access the release under the Investors tab on our company website, eladon.com. Before we begin, I would like to remind everyone that statements made during this conference call relating to Alidon's expected future performance, future business prospects, or future events or plans may include forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual outcomes and results could differ materially from these forecasts, due to the impact of many factors beyond the control of Eladon. Eladon expressly disclaims any duty to provide updates to its forward-looking statements, whether as a result of new information, future events, or otherwise. Participants are directed to the risk factors set forth in Eladon's reports, followed with the Securities and Exchange Commission. It is now my pleasure to pass the call to our CEO, Dr. David Alexander Groh. DA?

Thank you, John, and good afternoon, everyone. We made good progress during the first quarter, advancing both our company and our lead molecule, AT1501. I'm excited by the promise offered to us by AT1501 as a potential therapeutic for organ or cellular transplantation, ALS, and serious immunological diseases where patients face limited treatment options. Steve will go into details. around AT1501 program updates, but at a high level in the first quarter of this year, we continue to enroll patients into and remain on track for our ongoing ALS Phase II study. We reopened our Canadian site for our Phase II islet cell transplantation study for the treatment of type 1 diabetes, and we received FDA feedback and updated our development strategy in renal transplantation. Operationally, we completed our evolution into Elladon Pharmaceuticals from Novus Therapeutics. We also bolstered our senior leadership team to help us execute on our plans and achieve our short and long-term goals. Regarding the team, I'm extremely pleased to introduce four new executives, Paul Little as Chief Financial Officer, Jeff Bornstein as Chief Medical Officer, David Hovland as Chief Regulatory Officer, and Brian Smith as General Counsel, Corporate Secretary, and Chief Compliance Officer. With them on board, I'm thrilled that we've built out a top-tier leadership team that I believe positions us to achieve success for the benefit of patients and shareholders alike. I will now turn the call over to Steve Perrin, our President and Chief Scientific Officer, to discuss our clinical programs, after which Paul Little will provide a financial update. Steve, please go ahead.